SIETES :: 93213 citas

Resultados de la búsqueda por ANTIDEPRESIVOS REFINAR BÚSQUEDA

1.

Gerhard T, Stroup TS, Correll CU, Setoguchi S, Strom BL, Huang C, Tan Z, Crystal S, Olfson M. Mortality risk of antipsychotic augmentation for adult depression. PLoS One 2020;5:30 de septiembre. [Ref.ID 103735]

2.

Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Rajagopalan B, On behalf of the American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias. A scientific statement from the American Heart Association. Circulation 2020;142:16 de septiembre. [Ref.ID 103712]

3.

Sun JW, Hernández-Díaz S, Haneuse S, Bourgeois FT, Vine SM, Olfson M, Bateman BT, Huybrechts KF. Association of selective serotonin reuptake inhibitors with the risk of type 2 diabetes in children and adolescents. JAMA Psychiatry 2020:1. [Ref.ID 103710]

4.

Hart LA, Phelan EA, Yi JY, Marcum ZA, Gray SL. Use of fall eisk-increasing drugs around a fall-related injury in older adults: a systematic review. J Am Geriatr Soc 2020;68:junio. [Ref.ID 103662]

5.

Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom 2020;7:abril. [Ref.ID 103647]

6.

Reisman Y. Post-SSRI sexual dysfunction. BMJ 2020;368:27 de febrero. [Ref.ID 103567]

7.

Kondo KK, Morasco BJ, Nugent SM, Ayers CK, O'Neil ME, Freeman M, Kansagara D. Pharmacotherapy for the treatment of cannabis use disorder: a systematic review. Ann Intern Med 2020;172:junio. [Ref.ID 103546]

8.

Mahase E. Esketamine for treatment resistant depression is not recommended by NICE. BMJ 2020;368:30 de enero. [Ref.ID 103542]

9.

Just KS, Dormann H, Böhme M, Schurig M, Schneider KL, Steffens M, Dunow S, Plank-Kiegele B, Ettrich K, Seufferlein T, Gräff I, Igel S, Schricker S, Jaeger SU, Schwab MStingl J. Personalising drug safety—results from the multi-centre prospective observational study on Adverse Drug Reactions in Emergency Departments (ADRED). Eur J Clin Pharmacol 2020;76:marzo. [Ref.ID 103531]

10.

Sys J, Van Cleynenbreugel S, Deschodt M, Van der Linden L, Tournoy J. Efficacy and safety of non-benzodiazepine and non-Z-drug hypnotic medication for insomnia in older people: a systematic literature review. Eur J Clin Pharmacol 2020;76:marzo. [Ref.ID 103530]

11.

Parsons L. NICE knocks back J&J’s depression nasal spray Spravato Cites clinical and pricing uncertainty as basis of rejection. PMLiVE 2020:28 de enero. [Ref.ID 103516]

12.

Anónimo. Neurontin, Gralise, Horizant (gabapentin) and Lyrica, Lyrica CR (pregabalin): Drug safety communication - Serious breathing problems. U.S. Food and Drug Administration 2019:19 de diciembre. [Ref.ID 103239]

13.

Taylor P. J&J gets EU approval for depression nasal spray Spravato. PMLiVE 2019:20 de diciembre. [Ref.ID 103234]

14.

Healy D, Mangin D. Clinical judgments, not algorithms, are key to patient safety. BMJ 2019;367:2 de octubre. [Ref.ID 103204]

15.

Iacobucci G. NICE updates antidepressant guidelines to reflect severity and length of withdrawal symptoms. BMJ 2019;367:18 de octubre. [Ref.ID 103202]

16.

Pinzani V, Ladhari C. Jeux pathologiques : pas seulement les agonistes dopaminergiques !. BIP Occitanie 2019;26:octubre. [Ref.ID 103198]

17.

Moncrieff J. Re: Esketamine for treatment resistant depression. Putting drug company interests over the public good. BMJ 2019;366:23 de septiembre. [Ref.ID 103196]

18.

Dandjinou M, Sheehy O, Bérard A. Antidepressant use during pregnancy and the risk of gestational diabetes mellitus: a nested case–control study. BMJ Open 2019;9:. [Ref.ID 103190]

19.

Schäfer W, Princk C, Kollhorst B, Schink T. Antidepressants and the risk of hemorrhagic stroke in the elderly: a nested case–control study. Drug Saf 2019;42:septiembre. [Ref.ID 103178]

20.

Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D spending on single-enantiomer drugs versus their racemic precursors . Ann Intern Med 2019:13 de agosto. [Ref.ID 103162]